Clinical trial NCT02859623: Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)
Official title: Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN): a Retrospective Study of Patients Diagnosed in France From 2000 to 2013
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm
Hematological Malignancies
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2016-08-09
Enrollment: 86
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study concerns patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) from January 2000 to June 2013.

Brief summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease characterized by an aggressive clinical behavior and a poor prognosis. It predominantly affects elderly males with an average age of 67 years at diagnosis and the affected organs are usually the skin, bone marrow, lymph nodes and the central nervous system. Patients with BPDCN have poor outcomes with median overall survival (OS) ranging in the largest series of patients from 8 to 12 months.

Patient care must be defined in this pathology. Despite 40%-90% complete remission (CR) rates after initial chemotherapy, relapses are almost inevitable.

The investigators have developed a national network to collect clinical and biological data of French patients diagnosed with BPDCN.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) from January 2000 to June 2013 in France.
* Diagnosis should be established by hematology laboratory of French blood Agency of Bourgogne Franche-Comté and/or by anatomopathological analysis (realized in local centres or by Tony Petrella at Dijon University Hospital) according to phenotypic and anatomopathological criteria published in the literature.

Exclusion Criteria:

* No exclusion criteria

Primary outcomes:
measure: description of the efficacy of treatments for BPDCN
timeFrame: from the diagnosis to death or until June 2013, date of end of data collection
Secondary outcomes:
measure: description of clinical profiles of patients
timeFrame: from the diagnosis to death or until June 2013, end of data collection
measure: description of biological profiles of patients
timeFrame: from the diagnosis to death or until June 2013, end of data collection
measure: complete remission rate
timeFrame: from the diagnosis to death or until June 2013, end of data collection
measure: mean duration of the first remission
timeFrame: from the diagnosis to death or until June 2013, end of data collection
measure: survival without events
timeFrame: from the diagnosis to death or until June 2013, end of data collection
measure: non-responders rate
timeFrame: from the diagnosis to death or until June 2013, end of data collection
measure: time interval between two treatments
timeFrame: from the diagnosis to death or until June 2013, end of data collection
measure: mortality without relapse
timeFrame: from the diagnosis to death or until June 2013, end of data collection
Other outcomes:
Locations:
Study officials:
References: